专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

CN1239512A 脊髓灰质炎病毒具有复制能力的重组体萨宾I型株系无效
公开(公告)号：CN1239512A
公开(公告)日：1999-12-22
申请号：CN98801323.1
申请日：1998-08-07
申请人：奥尔特威尔生物技术公司
发明人：裴容洙 , 郑彗兰
IPC分类号： C12N15/63 , C12N5/10 , C12N15/48 , C12N15/51
CPC分类号： C07K14/005 , A61K39/00 , C12N15/86 , C12N2740/16122 , C12N2740/16222 , C12N2770/32643 , Y02A50/466
摘要：本发明提供了含有编码多克隆位点和3C－蛋白酶切割位点之序列的具有复制能力的重组体萨宾Ⅰ型脊髓灰质炎病毒载体。该载体使之易于将病毒疫苗基因从传染性病毒中引入萨宾Ⅰ型脊髓灰质炎病毒内，并产生嵌合萨宾Ⅰ型脊髓灰质炎病毒，期望能成为抵抗一些传染性病毒疾病的有效口服粘膜疫苗。

2. 发明公开

EP1102851A1 RECOMBINANT POLIOVIRUS FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：重组脊髓灰质炎病毒等用于治疗癌症的用途
公开(公告)号：EP1102851A1
公开(公告)日：2001-05-30
申请号：EP99917388.3
申请日：1999-04-09
申请人： THE RESEARCH FOUNDATION OFSTATE UNIVERSITY OF NEW YORK
发明人： GROMEIER, Matthias , WIMMER, Eckard
IPC分类号： C12N15/41 , A61K35/76 , C12N7/01 , C12N7/04
CPC分类号： C12N15/86 , A61K35/768 , A61K48/00 , C12N2770/32632 , C12N2770/32643 , C12N2840/203 , Y02A50/465
摘要： The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3'NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, an almost universally fatal neoplasm of the central nervous system.

3. 发明申请

WO2002072027A2 ONCOLYTIC RNA REPLICONS 审中-公开
公开(公告)号：WO2002072027A2
公开(公告)日：2002-09-19
申请号：PCT/US2002/007646
申请日：2002-03-13
申请人： UNIVERSITY OF ALABAMA RESEARCH FOUNDATION , REPLICON TECHNOLOGIES, INC.
发明人： ANSARDI, David, C. , MORROW, Casey, D. , PORTER, Donna, C.
IPC分类号： A61K
CPC分类号： A61K48/0008 , A61K31/203 , A61K31/555 , A61K35/76 , A61K38/204 , A61K48/00 , C07K14/70596 , C12N15/86 , C12N2770/32632 , C12N2770/32643 , C12N2830/00 , C12N2830/15 , C12N2830/60 , Y02A50/465 , A61K2300/00
摘要： The limited efficacy and/or toxicity of conventional therapies for many types of human cancers underscores the need for development of safe and effective alternative treatments. Towards this goal, the invention describes the direct oncolytic activity of RNA-based vectors derived from poliovirus, termed replicons, which are genetically incapable of producing infectious virus. Replicons of the invention are cytopythic in vivo for human tumor cells originating from brain, breast, lung, ovaries and skin (melanoma). Injection of replicons into established xenograft flank tumors in scid mice resulted in oncolytic activity and extended survival. Inoculation of replicons into established intracranial xenografts tumors in scid mice resulted in tumor infection and extended survival. Histological analysis revealed that replicons infected tumors cells at the site of inoculation and, most importantly, diffused to infect tumor cells which had metastasized from the initial site of implementation. The wide spectrum of cytopathic activity for human tumors combined with effective distribution following in vivo inoculation establishes the therapeutic potential of poliovirus replicons for a variety of cancers.
摘要翻译：常规治疗对许多类型人类癌症的有限效力和/或毒性有助于开发安全有效的替代治疗。为实现这一目标，本发明描述了衍生自脊髓灰质炎病毒（称为复制子）的基于RNA的载体的直接溶瘤活性，其在遗传上不能产生感染性病毒。对于源于脑，乳腺，肺，卵巢和皮肤（黑素瘤）的人类肿瘤细胞，本发明的复制物在体内是胞质连接的。在scid小鼠中将复制子注射入建立的异种移植物侧翼肿瘤中导致溶瘤活性和延长的存活。在scid小鼠中将复制子接种到建立的颅内异种移植物肿瘤中导致肿瘤感染并延长存活。组织学分析显示，复制子在接种部位感染肿瘤细胞，最重要的是扩散到感染起始部位转移的肿瘤细胞。人体肿瘤的广谱细胞病变活性与体内接种后的有效分布相结合，为各种癌症提供了脊髓灰质炎病毒复制子的治疗潜力。

4. 发明公开

EP1087017A3 The cytoplasmic inhibition of gene expression 失效
标题翻译：基因表达的细胞质抑制
公开(公告)号：EP1087017A3
公开(公告)日：2001-11-28
申请号：EP00127988.4
申请日：1995-05-26
申请人： Large Scale Biology Corporation
发明人： Donson, Jonathan , Della-Cioppa, Guy , Kumagai, Monto
IPC分类号： C12N15/83 , C12N15/82 , C12N5/10 , A01H5/00
CPC分类号： C12N15/1137 , C07K14/005 , C07K14/415 , C07K14/70571 , C12N9/00 , C12N9/0059 , C12N9/0071 , C12N9/0083 , C12N9/1074 , C12N9/1085 , C12N9/14 , C12N9/16 , C12N9/18 , C12N9/20 , C12N9/6459 , C12N9/78 , C12N9/84 , C12N15/8203 , C12N15/8216 , C12N15/8218 , C12N15/8249 , C12N15/825 , C12N15/8289 , C12N15/86 , C12N2710/22043 , C12N2710/22062 , C12N2750/12043 , C12N2770/00022 , C12N2770/00043 , C12N2770/00051 , C12N2770/32643 , C12N2770/32662 , C12N2770/32722 , C12N2770/32743 , C12N2770/32762 , C12N2770/36143 , C12N2770/36162 , C12N2799/021 , C12N2810/609 , C12P41/003 , C12Y114/18001 , C12Y302/01031 , C12Y304/21069 , G01N2333/4353
摘要： The present invention concerns a viral genetic vector derived from a positive single-stranded virus capable of replication in the cytoplasm of a plant cell. Furthermore, the invention concerns a method of producing a plant cell having reduced expression of a gene of interest and it concerns the plant cell itself. In addition, the present invention concerns a plant comprising a plurality of the plant cells.
摘要翻译：本发明涉及源自能够在植物细胞的细胞质中复制的阳性单链病毒的病毒遗传载体。此外，本发明涉及生产目的基因表达降低的植物细胞的方法，其涉及植物细胞本身。另外，本发明涉及包含多个植物细胞的植物。

5. 发明公开

EP1087017A2 The cytoplasmic inhibition of gene expression 失效
标题翻译：细胞质抑制抑制基因表达
公开(公告)号：EP1087017A2
公开(公告)日：2001-03-28
申请号：EP00127988.4
申请日：1995-05-26
申请人： Biosource Technologies, Inc.
发明人： The designation of the inventor has not yet been filed
IPC分类号： C12N15/83 , C12N15/82 , C12N5/10 , A01H5/00
CPC分类号： C12N15/1137 , C07K14/005 , C07K14/415 , C07K14/70571 , C12N9/00 , C12N9/0059 , C12N9/0071 , C12N9/0083 , C12N9/1074 , C12N9/1085 , C12N9/14 , C12N9/16 , C12N9/18 , C12N9/20 , C12N9/6459 , C12N9/78 , C12N9/84 , C12N15/8203 , C12N15/8216 , C12N15/8218 , C12N15/8249 , C12N15/825 , C12N15/8289 , C12N15/86 , C12N2710/22043 , C12N2710/22062 , C12N2750/12043 , C12N2770/00022 , C12N2770/00043 , C12N2770/00051 , C12N2770/32643 , C12N2770/32662 , C12N2770/32722 , C12N2770/32743 , C12N2770/32762 , C12N2770/36143 , C12N2770/36162 , C12N2799/021 , C12N2810/609 , C12P41/003 , C12Y114/18001 , C12Y302/01031 , C12Y304/21069 , G01N2333/4353
摘要： The present invention concerns a viral genetic vector derived from a positive single-stranded virus capable of replication in the cytoplasm of a plant cell. Furthermore, the invention concerns a method of producing a plant cell having reduced expression of a gene of interest and it concerns the plant cell itself. In addition, the present invention concerns a plant comprising a plurality of the plant cells.
摘要翻译：本发明涉及来自能够在植物细胞的细胞质中复制的阳性单链病毒的病毒遗传载体。此外，本发明涉及一种生产具有降低目标基因表达的植物细胞的方法，并涉及植物细胞本身。此外，本发明涉及包含多个植物细胞的植物。

6. 发明公开

EP1296720A2 POLIOVIRUS REPLICONS ENCODING THERAPEUTIC AGENTS AND USES THEREOF 审中-公开
标题翻译：脊髓灰质炎病毒复制子对于治疗有源代码及其用途
公开(公告)号：EP1296720A2
公开(公告)日：2003-04-02
申请号：EP01928531.1
申请日：2001-04-13
申请人： THE UAB RESEARCH FOUNDATION
发明人： MORROW, Casey, D. , JACKSON, Cheryl , PEDUZZI, Jean
IPC分类号： A61K48/00 , C12N15/86 , A61P25/00 , A61P35/00 , A61P31/04
CPC分类号： A61K39/105 , A61K38/191 , A61K48/00 , A61K2039/5256 , C12N15/86 , C12N2770/32634 , C12N2770/32643 , Y02A50/466
摘要： The invention pertains to methods of delivering a polypeptide to a cell comprising (a) contacting a cell with a replicon having a non-poliovirus nucleic acid substituted for a nucleic acid which encodes at least a portion of a protein necessary for encapsidation, the non-poliovirus nucleic acid encoding, in an expressible form, a polypeptide or fragment thereof; and (b) maintaining the cells under conditions appropriate for introduction of the replicons into the cells. The cell may be within a subject and the polypeptide may be a therapeutic agent. The methods of the invention may be used to treat diseases including central nervous system disorders, infectious diseases, and cancer.

7. 发明公开

EP0966538A1 REPLICATION-COMPETENT RECOMBINANT SABIN TYPE 1 STRAIN OF POLIOVIRUS 审中-公开
标题翻译：复制能力的，重组体脊髓灰质炎病毒的Sabintyp 1株
公开(公告)号：EP0966538A1
公开(公告)日：1999-12-29
申请号：EP98938993.0
申请日：1998-08-07
申请人： Altwell Biotech. Inc.
发明人： BAE, Yong Soo , JUNG, Hye Rhan
IPC分类号： C12N15 , C07K14 , C12N5 , A61K39
CPC分类号： C07K14/005 , A61K39/00 , C12N15/86 , C12N2740/16122 , C12N2740/16222 , C12N2770/32643 , Y02A50/466
摘要： A replication-competent recombinant Sabin type 1 poliovirus vector containing a sequence coding for multiple cloning site and 3C-protease cleavage site is provided. This vector makes it easy to introduce various vaccine genes from infectious viruses to the Sabin 1 poliovirus, and facilitates to produce chimeric Sabin 1 polioviruses that are expected to be powerful oral mucosal vaccines against several infectious viral diseases.

8. 发明专利

JP2004000274A Nucleic acid of recombinant virus 审中-公开
公开(公告)号：JP2004000274A
公开(公告)日：2004-01-08
申请号：JP2003300621
申请日：2003-08-25
申请人： Large Scale Biology Corp , ラージ・スケール・バイオロジー・コーポレイションLarge Scale Biology Corporation
发明人： DONSON JON , DAWSON WILLIAM O , GRANTHAM GEORGE L , TURPEN THOMAS H , TURPEN ANN M , GARGER STEPHEN J , GRILL LAURENCE K
IPC分类号： A01K67/027 , C07K14/08 , C07K14/095 , C07K14/415 , C12N5/10 , C12N9/00 , C12N9/02 , C12N9/10 , C12N9/14 , C12N9/16 , C12N9/18 , C12N9/20 , C12N9/24 , C12N9/72 , C12N9/78 , C12N9/84 , C12N15/00 , C12N15/09 , C12N15/113 , C12N15/12 , C12N15/40 , C12N15/82 , C12N15/83 , C12N15/86 , C12P21/02 , C12P41/00 , C12R1/91 , C12R1/92
CPC分类号： C07K14/005 , C07K14/415 , C12N9/00 , C12N9/0059 , C12N9/0071 , C12N9/0083 , C12N9/1074 , C12N9/14 , C12N9/16 , C12N9/18 , C12N9/20 , C12N9/6459 , C12N9/78 , C12N9/84 , C12N15/1137 , C12N15/8203 , C12N15/8216 , C12N15/8218 , C12N15/8249 , C12N15/825 , C12N15/8289 , C12N15/86 , C12N2710/22043 , C12N2710/22062 , C12N2750/12043 , C12N2770/00043 , C12N2770/00051 , C12N2770/32643 , C12N2770/32662 , C12N2770/32743 , C12N2770/32762 , C12N2770/36143 , C12N2770/36162 , C12N2810/609 , C12P41/003 , C12Y114/18001 , C12Y204/01019 , C12Y302/01031 , C12Y304/21069
摘要： PROBLEM TO BE SOLVED: To provide a new nucleic acid of recombinant virus, and to provide a method for producing a desired product. SOLUTION: The recombinant virus nucleic acid is one selected from (+) sense linear RNA viruses having natural or nonnatural subgenomic promoter, wherein the recombinant virus nucleic acid comprises a nonnatural nucleic acid sequence cording a nonnatural protein, transfers the nonnatural nucleic acid in a host and forms the nonnatural protein. COPYRIGHT: (C)2004,JPO

9. 发明公开

EP0832191A4 RECOMBINANT VIRAL NUCLEIC ACIDS 失效
标题翻译：重组病毒核酸
公开(公告)号：EP0832191A4
公开(公告)日：2000-11-15
申请号：EP96919165
申请日：1996-06-06
申请人： BIOSOURCE TECH INC
发明人： DONSON JON , DAWSON WILLIAM O , GRANTHAM GEORGE L , TURPEN THOMAS H , TURPEN ANN M , GARGER STEPHEN J , GRILL LAURENCE K
IPC分类号： A01K67/027 , C07K14/08 , C07K14/095 , C07K14/415 , C12N5/10 , C12N9/00 , C12N9/02 , C12N9/10 , C12N9/14 , C12N9/16 , C12N9/18 , C12N9/20 , C12N9/24 , C12N9/72 , C12N9/78 , C12N9/84 , C12N15/00 , C12N15/09 , C12N15/113 , C12N15/12 , C12N15/40 , C12N15/82 , C12N15/83 , C12N15/86 , C12P21/02 , C12P41/00 , C12R1/91 , C12R1/92 , C12N5/00
CPC分类号： C07K14/005 , C07K14/415 , C12N9/00 , C12N9/0059 , C12N9/0071 , C12N9/0083 , C12N9/1074 , C12N9/14 , C12N9/16 , C12N9/18 , C12N9/20 , C12N9/6459 , C12N9/78 , C12N9/84 , C12N15/1137 , C12N15/8203 , C12N15/8216 , C12N15/8218 , C12N15/8249 , C12N15/825 , C12N15/8289 , C12N15/86 , C12N2710/22043 , C12N2710/22062 , C12N2750/12043 , C12N2770/00043 , C12N2770/00051 , C12N2770/32643 , C12N2770/32662 , C12N2770/32743 , C12N2770/32762 , C12N2770/36143 , C12N2770/36162 , C12N2810/609 , C12P41/003 , C12Y114/18001 , C12Y204/01019 , C12Y302/01031 , C12Y304/21069
摘要： The present invention relates to a recombinant viral nucleic acid selected from a (+) sense, single stranded RNA virus possessing a native subgenomic promoter encoding for a first viral subgenomic promoter, a nucleic acid sequence that codes for a viral coat protein whose transcription is regulated by the first viral subgenomic promoter, a second viral subgenomic promoter and a second nucleic acid sequence whose transcription is regulated by the second viral subgenomic promoter. The first and second viral subgenomic promoters of the recombinant viral nucleic acid do not have homologous sequences relative to each other. The recombinant viral nucleic acid provides the particular advantage that it systematically transcribes the second nucleic acid in the host. Host organisms encompassed by the present invention include procaryotes and eucaryotes, particularly animals and plants. The present invention also relates to viruses containing the viral vectors which are infective, production cells which are capable of producing the viruses or parts thereof, a host infected by the viruses of the invention, the gene products produced by expression of the viral nucleic acids and a process for the production of a desired product by growing the infected hosts.

10. 发明公开

EP0937151A1 HEPATITIS C SURROGATE VIRUS FOR TESTING THE ACTIVITY OF HEPATITIS C VIRUS PROTEASE, A RECOMBINANT GENE AND A USE THEREOF 失效
标题翻译：丙型肝炎病毒的替代，用于测试丙型肝炎病毒特异性蛋白酶，重组基因及其应用程序的活动
公开(公告)号：EP0937151A1
公开(公告)日：1999-08-25
申请号：EP97927459.0
申请日：1997-06-25
申请人： LG Chemicals Co., Ltd. , Pohang University of Science and Technology Foundation
发明人： JANG, Sung Key , HAHM, Bum Suk
IPC分类号： G01N33 , C07K14 , C12N15 , C12Q1 , C12R1
CPC分类号： C07K14/005 , C12N2770/24222 , C12N2770/32643
摘要： The recombinant poliovirus which comprises poliovirus, hepatitis C virus (HCV) protease NS3 and target sites of the hepatitis C virus protease NS3, and needs the HCV protease activity, is produced, because efficient culture system for drugs against hepatitis C virus (HCV) which is the major etiologic agent of non-A, non-B hepatitis is lack.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式